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ABSTRACT  
There are a paucity of data describing the impact of salt counterions on the biological 
performance of inhaled medicines  . The aim of this study was to determine if the co
administration of salt counterions influenced the tissue permeability and the airway smooth 
muscle relaxation potential of salbutamol, formoterol and salmeterol. The results demonstrated 
that only salbutamol, when formulated with an excess of the 1hydroxy2naphthoate (1H2NA) 
counterion, exhibited a superior bronchodilator effect (%< 0.05) compared to salbutamol base. 
The counterions aspartate, maleate, fumarate and 1H2NA had no effect on the ability of 
formoterol or salmeterol to reduce airway resistance  . Studies using guinea pig tracheal 
sections showed that the salbutamol:1H2NA combination resulted in a significantly faster (%< 
0.05) rate of tissue transport compared to salbutamol base. Furthermore, when the relaxant 
activity of salbutamol was assessed  using electrically stimulated, superfused preparations 
of guinea pig trachea, the inhibition of contraction by salbutamol in the presence of 1H2NA was 
greater than with salbutamol base (a total inhibition of 94.13 %, %< 0.05). The reason for the 
modification of salbutamol’s behavior upon administration with 1H2NA was assigned to ionpair 
formation, which was identified using infrared spectroscopy. Ionpair formation is known to 
modify a drug’s physicochemical properties and the data from this study suggested that the 
choice of counterion in inhaled pharmaceutical salts should be considered carefully as it has the 
potential to alter drug action . 
KEYWORDS: salbutamol; ionpair; airways; counterion; pharmaceutical salt; 1H2NA 
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ABBREVIATIONS: 1H2NA, 1hydroxy2naphthoate; β2AR, β2 adrenoceptor; COPD, chronic 
obstructive pulmonary disorder; i.m., intramuscular; i.v., intravenous; SEM, standard error of 
the mean; RPHPLC, reverse phase high performance liquid chromatography; SD; standard 
deviation; KH, KrebsHenseleit; EFS, electrical field stimulation; ANOVA, analysis of 
variance; SAL, salbutamol base; FTIR, Fourier transform infra red; Papp, apparent permeability; 
ASM, airway smooth muscle; OCTs, organic cation transporters. 
 
1. Introduction  
 A pharmaceutical salt is particularly susceptible to the composition of body fluids into 
which it dissolves because there is the potential that the drug can partake in a number of different 
noncovalent physical interactions. For example, if the pharmaceutical salt dissolves into a fluid 
that allows the drug to ionise, ionpairs can be formed in solution.
1
 Ionpairs usually arise from 
the drug interacting with coadministered salt counterions which can in turn modify a drugs 
physicochemical behaviour.
2
 
Not every pharmaceutical salt will be susceptible to ionpair formation upon dissolution 
in body fluids.
3
 The formation of an ionpair complex between the ionised drug and co
administered ionised counterion is dependent upon the physicochemical properties of the drug, 
the physicochemical properties of the ionpair, the affinity of the two molecules and the route of 
administration.
1
 For example, when administering a pharmaceutical salt orally the drug is 
exposed to a relatively large volume of liquid and hence, if a liable, noncovalent bond is formed 
between the drug and the counterion it will most probably be broken when faced by rapid 
dilution and competition from charged species in the gut fluids, unless the ionpair binding is 
very strong. Such a scenario has led to the regulatory approval of several salt forms of the same 
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drug for a single therapeutic indication when dosed orally because the different salt forms appear 
to be bioequivalent.
4
 However, this does not mean that all salts are bioequivalent. The biological 
consequences of delivering therapeutic agents as pharmaceutical salts via routes which do not 
expose the molecules to such a large volume of fluid, e.g. the skin and the airways, may be more 
significant compared to oral administration. 
Previous literature has suggested that changes in drug transmembrane permeation as a 
result of ionpair formation has a major influence on the ability of salt counterions to modify the 
parent drugs behaviour.
5–7
 In addition, data generated   has suggested that ionpairs can 
remain intact upon crossing biological barriers
8
 and therefore it may be possible that a parent 
drug’s behaviour may be influenced by a salt counterion, even after absorption into the body. 
However, there appears to be very limited information about the consequence of ionpair 
formation  
9
 This is surprising given the number of pharmaceutical salts that are used 
clinically and it suggests that further research into the manner of how coadministered counter
ions influence the biological behaviour of pharmaceutical salts is required. 
 The primary aim of this study was to investigate the potential of a coadministered 
counterion to alter the biological behaviour of a drug, which forms a pharmaceutical salt, 
The inhaled route was chosen for this study due to the low volume of liquid in which the 
drug and counterion dissolves and the fact that the ability of an ionpair to alter the 
physicochemical properties of an inhaled drug has already been established.
10
 The β2 
adrenoceptor (AR) agonists, salbutamol, salmeterol and formoterol were selected as the drug 
molecules in this work because they are all commercially available as pharmaceutical salts and 
are widely used clinically for the treatment of asthma and chronic obstructive pulmonary disease 
(COPD).
11
 In addition, salbutamol has already been studied with a number of counter
Page 6 of 37
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 6
ions including, sulphate,
10,12
 adipate, stearate,
10
 succinate,
12
 acetate monomethanolate,
13
 and 
hydrochloride,
14
 and this provided vital information upon which to base the  work. As the 
physical and chemical properties of the salbutamol salts have already been characterized 
10,12,15
 
this study initially focused on the pharmacodynamic consequences of drugcounterion co
administration. However, to better understand the drugcounterion mixtures that elicited 
changes in pharmacodynamics responses, an attempt was made to characterise the strength of the 
drug counterion interactions, to elucidate the effects of the counterions upon tissue permeation, 
and understand the influence of the counterions upon the drug’s pharmacological action. The 
counterions aspartate, maleate, fumarate and 1H2NA were selected to represent a series of 
compounds that were used clinically, displayed different physicochemical properties, and 
because they had the potential to form ionpairs with the β2AR agonists. The drugcounterion 
combinations used in the study were based upon the molecules compatibility in the solution state 
at the concentrations that were used in the work. As it was anticipated that the interaction affinity 
between the drug and counterions would be relatively weak the therapeutic agents were 
administered in all the studies with an excess of counterions to maximise the interactions 
between the β2AR agonist and the counterions. Whilst it was accepted that this does not 
necessarily mimic the use of a pharmaceutical salt  as they are typically presented to the 
body with lower counterion concentrations, the experiments were designed in this manner to 
continually present the test agents to different  and  systems in a similar state, even 
within the fluids used in assays varied. This was an essential experimental design trait of this 
work that allowed the study data to be directly compared across the test systems. In addition, to 
mimic the inhaled administration of ‘pharmaceutical salts’, which typically are produced as 
powders, a production method for each drugcounterion combination would be required to 
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produce the lowest energy salt form in the solidstate. This would be a considerable piece of 
work and the reporting of the physical data, which would be needed to support the use of these 
compounds, would detract from the  aspect of the study which was our focus. Therefore 
simple solutions of the drugs and the counterions were used as the test samples in this work. 
 
2.Materials and Methods 
&'	"	$	" 
 Salbutamol base (BN. H80619) was a kind gift from Cipla Ltd., Mumbai, India. 
Salbutamol sulphate (BN. B027798) was obtained from GlaxoSmithKline Research and 
Development, Ware, UK. Salmeterol xinafoate (BN. SX0081010) was purchased from Vamsi 
Labs, India. Salmeterol base and formoterol base were synthesised by Tocris Cookson Ltd., 
Avonmouth, Bristol, UK. Formoterol fumarate dihydrate (BN. 27000M0 A0031421) was 
obtained from Arena Pharmaceuticals, Buckingham, UK. Phosphate Buffered Saline (PBS) 
tablets (0.15 M, pH 7.3) were purchased from Oxoid, Basingstoke, UK. Whatman
TM
 nylon filters 
(pore size 0.2 µm, diameter 47 mm) were purchased from Fisher Scientific Ltd., Loughborough, 
UK. Methanol (Fisher Scientific Ltd, UK) and ammonium acetate (SigmaAldrich Company 
Ltd., Poole, Dorset, UK) were of high performance liquid chromatography (HPLC) grade. 
Indomethacin, sodium hydroxide, hydrochloric acid, 1hydroxy2naphthoate (1H2NA), 
bombesin acetate, maleic acid, Laspartic acid, sodium chloride, potassium chloride, calcium 
chloride dihydrate, magnesium sulphate, sodium bicarbonate, potassium dihydrogen phosphate, 
and Dglucose were all purchased from SigmaAldrich Company Ltd., Poole, Dorset, UK and 
were of analytical grade.  
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&&("
 Experiments were conducted under a project licence issued by the United Kingdom 
Home Office in accordance with the United Kingdom Animal Scientific Procedures Act, 1986. 
Protocols were approved by the Local Ethical Review Committee of King’s College London.  
All   experiments were performed with male DunkinHartley guinea pigs (250  500 g, 
Charles River). Guinea pigs were housed in animal holding facilities maintained at 18  19 °C 
with a standard 12 hour lightdark cycle. A maximum of six guinea pigs were housed per cage, 
containing sawdust and hay with cardboard tunnels in order to provide environmental 
enrichment. Animals were fed   ( on a FD1 guinea pig diet (Special Diets Services, 
Witham, Essex, UK) with free access to water. 
 
&)* $+ " 	"
Male DunkinHartley guinea pigs (250 – 500 g) were anaesthetised with urethane (25 % 
w/v, 7 ml kg
1
, i.p.) and a neuromuscular blocker was also administered to induce skeletal muscle 
paralysis (succinylcholine chloride, 1 mg kg
1
, i.m). The trachea, carotid artery and both jugular 
veins were cannulated for measurement of airway obstruction, systemic blood pressure, and for 
i.v. administration of test substances, respectively. An i.v. infusion was used to dose the ion
pairs, as this minimised the potential of non equivalent doses reaching the tissue as a 
consequence of differences in deposition and absorption via the inhaled route. The tracheal 
cannula was attached to a pneumotachograph that was in turn connected to a pressure transducer 
(± 2 cm H2O, model MP4514871, Validyne Engineering). Changes in airflow were measured 
using a lung function recording system (version 9.2; Mumed Systems, London, UK) and 
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displayed in real time on a personal computer. The flow signal was integrated to give a measure 
of tidal volume. A cannula was inserted into the thoracic cavity between the third and fifth ribs 
and connected to the negative side of the pressure transducer (± 20 cm H2O, Validyne). The 
positive side of the pressure transducer was connected to the side of the pneumotachograph 
proximal to the animal to obtain a measure of transpulmonary pressure (difference between 
mouth and thoracic pressure). The lung function parameter, total airway resistance (RL; cm of 
water per L per sec), was derived from each measure of flow, tidal volume, and transpulmonary 
pressure by integration. Animals were allowed to acclimatise for 10 min prior to the start of the 
study. 
For bronchodilator experiments, bronchoconstriction was induced by means of continuous 
i.v. administration of bombesin (2  4 µg kg
1
) which elicited sustained submaximal increases in 
total airway resistance, as described elsewhere.
16
 After stable bronchoconstriction had been 
obtained, salbutamol, formoterol or salmeterol base, alone or in the presence of the counterions, 
were cumulatively (0.1, 1, 10, 100 or 1000 µg kg
1
) administered through a separate cannula to 
reverse the bombesininduced bronchoconstriction. Salbutamol was formulated with sulfate as it 
was supplied (2:1 ratio) at 0.1, 1, 10, 100, or 1000 µg kg−1, and 1H2NA at a molar ratio of 1:10. 
Formoterol fumarate and salmeterol xinafoate were used as supplied at 0.1, 1, 10 or 100 µg 
kg−1. Formoterol base and salmeterol base were formulated with maleate or aspartate at a ratio 
of 1:10.. The dose was increased when the effect of the previous dose had reached a plateau. 
Bronchodilation was calculated as the percentage reversal of the increase in total lung resistance 
induced by bombesin. Data were expressed as arithmetic means ± standard error of the mean 
(SEM). 
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&, ( 	-	" 	"
 For the analysis of salbutamol in the presence of the hydrophobic counterion 1H2NA a 
UV/Vis spectrophotometer (Perkin Elmer Ltd., Beaconsfield, UK) was used. Standard stock 
solutions of salbutamol base and 1H2NA were prepared in deionised water (pH 6.5 measured 
using a pH meter) and adjusted using 0.1 M sodium hydroxide and/or hydrochloric acid. 
Solutions of salbutamol base and 1H2NA were mixed to achieve a concentration range of 0.005
0.84 mM for 1H2NA and a constant salbutamol base concentration of 0.42 mM, made up to 
volume using deionised water. The final pH of the samples were checked and adjusted to pH 
6.5. Samples were scanned between 190 and 400 nm using a UV Quartz cuvette (path length 10 
mm). A background reading of a ‘blank’ solution was preceded by three replicate readings of 
each sample. The spectral data was converted into an Excel file for analysis. 
For the infrared (IR) studies solutions of salbutamol base and salbutamol in the presence 
of sulphate were prepared in deuterated water, and deuterated methanol (80:20). Solutions of 
salbutamol base and salbutamol in the presence of 1H2NA were prepared in a 70:30 ratio of 
deuterated methanol to deuterated water. All samples were adjusted to pH 6.5 using 0.1 M 
sodium hydroxide and/or hydrochloric acid, and checked again at the end of the study. Spectra 
were obtained with the aid of a universal OmniCell system (Specac Ltd., Orpington, Kent, UK) 
for the analysis of liquids equipped with calcium fluoride (CaF2) windows (Mylar spacer at 
0.025 mm path length). A double solvent subtraction procedure was employed for all spectra. 
Samples were scanned on average 32 times, with a resolution of 4 cm
1
 over the 5504000 cm1 
range. Data was recorded using a Spectrum One spectrometer and spectral analysis was 
performed with Spectrum version 5.3.1 software (Perkin Elmer Ltd., Beaconsfield, UK). 
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&.* $/	"%" 	"
 Transport experiments were carried out in unjacketed, individually calibrated, upright 
Franz diffusion cells (MedPharm Ltd., UK). Guinea pigs were killed by a blow to the head, 
followed by exsanguination; the trachea was excised and placed in cold physiological saline (0.9 
% sodium chloride, pH 5.5). The adherent connective tissue was dissected away and the lumen 
gently flushed with saline. The trachea was dissected into rings consisting of 5  6 cartilage 
bands and mounted between the donor and receiver chambers, which were sealed together using 
parafilm. Small magnetic bars were inserted into each of the receiver compartments to ensure 
adequate mixing. The receiver compartments were filled with physiological saline (0.9 % sodium 
chloride, pH adjusted to 7.4) and each cell was checked by inversion for leaks. The assembled 
Franz cells were placed in a 37°C water bath and allowed to equilibrate for 60 min prior to 
adding 300 µL of the donor solution (salbutamol base, salbutamol sulphate (commercial salt) or 
salbutamol in the presence of 1H2NA). The salbutamol base concentration was fixed at 0.00178 
M for all test systems. An excess of 1H2NA was presented at a concentration of 17.8 x 10
3
 M to 
mimic the in vivo studies. All samples were made up to volume using deionised water (pH 7.4) 
and the final pH adjusted to 7.4 using 0.1 M sodium hydroxide or hydrochloric acid. Samples 
(0.2 mL) were taken for reverse phase high performance liquid chromatography (RPHPLC) 
analysis (method I or II detailed below) at 0 (prior to addition of the donor solution), 15, 30, 45, 
60, 120, 180, 240, 300, 360, 1320, 1380 and 1440 min after the donor solution was added to the 
cells. Following sampling each receiver cell compartment was replaced with fresh prewarmed 
physiological saline (0.9 % sodium chloride, pH adjusted to 7.4) of equal volume. The 
cumulative amount of drug (µg) transported through the trachea per unit area (cm
2
) was 
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corrected for sample removal and plotted against time (min). Steadystate flux was calculated 
using the line of best fit over a minimum of five time points with a linearity of R
2
 ≥ 0.97 and 
displayed as mean ± standard deviation (SD). Where appropriate a twotailed, unpaired, 
Student’s test was used and statistically analysed at the 95% confidence level. 
 
&0		"	%/"	/$/%	+(	1 /($%/23*#4
	/I  Separation of salbutamol base and salbutamol sulphate was achieved using a 
SphereClone ODS2 (250 x 4.6 mm, particle size: 5µm) column (Phenomenex® Ltd., Cheshire, 
UK) maintained at 50°C using a thermostatted column compartment, TCC100 (Dionex 
Corporation, Sunnyvale, CA, USA). The mobile phase was a mixture of aqueous ammonium 
acetate solution  0.1% and methanol (80:20) at pH 4.5, filtered through a 0.2 µm nylon 
membrane and degassed by sonication. The mobile phase flow rate was 1.0 mL min
1
, the 
injection volume was 20 µL and detection was set at 272 nm. Quantitative determination of the 
active substance was performed using a RPHPLC system consisting of a Dionex P680 pump, a 
Dionex PDA100 photodiode array detector and a Dionex ASI100 automated sampler injector 
with Chromeleon Client version 6.60 for analysis (Dionex Corporation, Sunnyvale, CA, USA).  
	/55  Separation of salbutamol base and salbutamol in the presence of 1H2NA was 
achieved using a SphereClone ODS2 column, maintained at 50°C using a thermostatted column 
block heater TCC100. The mobile phase was a mixture of aqueous ammonium acetate solution  
0.1% and methanol (80:20) at pH 6.0, filtered using a through a 0.2 µM nylon membrane and 
degassed by sonication. The stationary phase was used with a 1.2 mL min
1
 flow rate and a 20 
µL injection volume. The compounds were analysed at a wavelength of 276 nm.  
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Both RPHPLC methods were shown to be fit for purpose in terms of precision (≤ 2%), 
accuracy (≥ 99%), linearity (R
2
> 0.9999) and sensitivity (limit of detection < 0.53 µg mL
1
; limit 
of quantification < 1.78 µg mL
1
). A twotailed, unpaired, Student’s test determined no 
significant (%> 0.05) differences on average retention times between salbutamol base assayed 
alone or in the presence of counterions. 
 
&652+"	$ 	%$/	
Superfusion of guinea pig tracheal rings was performed according to a previously 
described method.
17,18
 Guinea pigs were sacrificed by cervical dislocation, and the trachea were 
excised and cut into rings. Each tracheal ring (3  5 cartilage bands) was opened by sectioning 
the ring opposite the smooth muscle and sectioned to form strips. A cotton thread was attached to 
the cartilage at one end of the strip for attachment to the tension gauge, and a cotton loop to the 
other end for anchoring the tissue to a fixed stainless steel hook. The tissue was then suspended 
between two platinum electrodes under 1g tension and superfused at a rate of 3 mL min
1
 
(WatsonMarlow SciQ 323S peristaltic pump and a 318MC eight roller five channel micro 
pump head, Cornwall, U.K.) through a jacketed, glass heat exchanger with KrebsHenseleit (K
H) solution (37°C, 5% CO2, 95% O2) containing the cyclooxygenase inhibitor, indomethacin (5 
µM) to inhibit the release of endogenous prostaglandins and reduce spontaneous tone of the 
airway smooth muscle.  
KH solution (pH 7.2 – 7.4) was composed of: 118 mM sodium chloride, 4.7 mM 
potassium chloride, 2.5 mM calcium chloride dihydrate, 1.2 mM magnesium sulphate, 25 mM 
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sodium bicarbonate, 1.2 mM potassium dihydrogen phosphate, and 11.1 mM Dglucose made up 
to volume in deionised water.  
The tracheal preparations were equilibrated for 40 min before commencement of electrical 
field stimulation (EFS) delivered as 10 s trains of square wave pulses at 3 HZ, 0.1 ms duration 
and 30 v generated every 100 s by means of a physiological square wave stimulator (Digitimer 
MultistimSystemD330, Digitimer Ltd, Herts, U.K.). Changes in tension detected by the tension 
gauge were recorded using a Powerlab/8sp (AD Instruments, Castle Hill, Australia). Ten minutes 
after the initiation of airway smooth muscle stimulation, the trachea was superfused with KH 
solution containing the drug of interest by slow infusion. The drug was delivered at a rate of 
0.275 mL min
1
 using a syringe pump (OriginalPerfusorSpritze, B. Braun Medical, Melsungen, 
Germany) to which a butterfly25G short winged infusion tube (Abbott, Sligo, Republic of 
Ireland) was attached for 20 min, after which superfusion with drug was terminated. The tissues 
were then superfused with drug free KH solution and tension was monitored for a further 6 h. 
The maximumminimum (g) peak height for the period of contraction was calculated offline by 
using LabChart 7 Reader software (AD Instruments, Hastings, UK).  
All EFS data are expressed as percentage inhibition of the contractile response obtained 
prior to the administration of the drug and displayed as mean ± standard error of the mean 
(SEM). Onset time (OT50 and OT75) was expressed as the time taken from administration of the 
drug to achieve 50% or 75% control (predrug) value (minutes) and was determined by 
interpolation from the plot of percentage against time to attain 50% or 75% inhibition of the 
response. Likewise, the recovery (or offset) time (RT50 and RT75) was expressed as the time 
taken from stopping the administration of the drug to achieve 50% or 75% recovery of the 
contractile response (predrug) value (minutes). It was determined by interpolation from a plot of 
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percentage response (% control) against time to attainment of 50% or 75% recovery from that 
response.  
Data was analysed using a KruskalWallis nonparametric oneway analysis of variance 
(ANOVA) with posthoc Dunn's Multiple Comparison test. The final concentration of 
salbutamol base on the tissue remained constant at 1 µM. The hydrophobic counterion, 1H2NA, 
was added to salbutamol base (1 µM) in excess of 10 fold (10 µM). Salbutamol sulphate was at a 
total concentration of 1 µM. All samples were made up to volume in deionised water and 
adjusted to pH 7.4 with 1 M sodium hydroxide and/or hydrochloric acid. 

&7""2""
All data analysis was performed using Graphpad Prism (Prism, version 5; GraphPad 
Software Inc., San Diego, CA). Data was analysed for normality using the AndersonDarling 
test. Where appropriate a twotailed, unpaired, Student’s test was used and statistically 
analysed at the 95% confidence level. 5  data was analysed using a one way ANOVA 
KruskalWallis test with posthoc Dunn's multiple comparison test. 5  data was analysed 
using a oneway analysis of variance (ANOVA) with a posthoc Tukey's Multiple Comparison 
test or a twoway ANOVA with posthoc Bonferroni test and considered significant at a % value 
less than 0.05.  
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3.Results 
 
)'8/	 	++	 + " ( "	 " ( " %/	  " (  /	 %	"		 +
'&9 $+  
An i.v. infusion of the peptide bombesin induced an increase in airways resistance in all 
animals (Figure 1). A 100 % increase in resistance was desired and the dose of bombesin was 
adjusted accordingly. Bombesin induced airway obstruction by 85  123 % in all animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Representative trace of changes in total lung resistance following i.v. administration of 
bombesin (2 µg kg
1
), followed by i.v. administration of salbutamol base (SAL) at regular 
intervals (0.1, 1, 10, 100 and 1000 µg kg
1
). 
 
Salbutamol base (0.1, 1, 10, 100 and 1000 µg kg
1
), salbutamol sulphate (0.1, 1, 10, 100 
and 1000 µg kg
1
) and salbutamol in the presence of 1H2NA (0.1:1, 1:10, 10:100 µg kg
1
) all 
elicited a doserelated reduction in the bombesin induced resistance (Figure 2). These data seem 
Page 17 of 37
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 17
to suggest that the bronchodilator effect of the different salbutamol products differed between the 
treatment groups (Figure 2, Supporting Information Figure S1). Salbutamol in the presence of 
1H2NA at 10 µg kg
1
 reversed peak resistance by 81.30 ± 3.59 % (n = 7) (%< 0.05, twoway 
ANOVA with posthoc Bonferroni test vs. salbutamol base), whereas at a similar dose, 
salbutamol sulphate only reversed peak resistance by 59.44 ± 6.78 % (n = 5), and salbutamol 
base by only 52.47 ± 11.92 %. 
Figure 2. Bronchodilating effect of Salbutamol 
base (0.1, 1, 10, 100 and 1000 µg kg
1
, pH 7.4), 
salbutamol sulphate (0.1, 1, 10, 100 and 1000 
µg kg
1
, pH 7.4) and salbutamol in the presence 
of 1H2NA (0.1:1, 1:10, 10:100 µg kg
1
, pH 7.4) 
on bombesininduced increase in total lung 
resistance. Points represent mean ± S.E.M;  = 3 
– 7. Twoway ANOVA with posthoc 
Bonferroni test, (*) %< 0.05 vs. salbutamol base. 
 
)&8/		++	 	-" $+  %("++(	"(		 
Formoterol base (0.1, 1 and 10 µg kg
1
), formoterol fumarate (0.1, 1 and 10 µg kg
1
), 
formoterol in the presence of maleate, and formoterol in the presence of aspartate (0.1:1, 1:10, 
10:100 µg kg
1
) all elicited a doserelated reduction in resistance induced by bombesin (Figure 3, 
Supporting Information Figure S2). However, the percentage reversal of airway obstruction of 
the different formoterol products was very similar (Figure 3).  
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Figure 3. Bronchodilator effect of 
formoterol base (0.1, 1 and 10 µg kg
1
, 
pH 7.4), formoterol fumarate (0.1, 1 and 
10 µg kg
1
, pH 7.4), formoterol in the 
presence of maleate, and formoterol in 
the presence of aspartate (0.1:1, 1:10 
and 10:100 µg kg
1
, pH 7.4) on 
bombesininduced increases in total 
lung resistance. Points represent mean ± 
S.E.M;  = 3 – 4.  
 
Salmeterol base appeared to have a very different doseresponse profile compared to 
salbutamol and formoterol; for example, salmeterol displayed very little relaxation of the tissue 
at 0.1 and 1 µg kg
1
 unlike the other bronchodilators (Figure 4, Supporting Information Figure 
S3). However, as with formoterol, the presence of counterions did not seem to influence the 
performance of salmeterol, i.e., all the dose response profiles were similar both with and without 
the salt counterions (Figure 4). Only salmeterol maleate showed a significantly slower effect at 
reversing peak resistance compared to salmeterol xinafoate, but only at 10 µg kg
1
 (%< 0.05, two
tailed unpaired, Student’s test) (Figure 4).   
 
Figure 4. Bronchodilator effect 
of salmeterol base (0.1, 1, 10 and 
100 µg kg
1
, pH 7.4), salmeterol 
xinafoate (0.1, 1, 10 and 100 µg 
kg
1
, pH 7.4), salmeterol in the 
presence of maleate and 
salmeterol in the presence of 
aspartate (0.1:1, 1:10, 10:100 and 
100:1000 µg kg
1
, pH 7.4) on 
bombesininduced increase in total lung resistance. Points represent mean ± S.E.M;  = 3 – 5. 
Twotailed unpaired, Student’s test. (*) %< 0.05 vs. salmeterol xinafoate.  
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)) ( 	-	" 	" 
Using Fourier transform infrared spectroscopy (FTIR) measurements the salbutamol base 
sample showed a peak at 1606 cm
1
 in solution, which was assigned to the secondary amine 
(Figure 5). A significant shift in this secondary amine bend was observed for salbutamol base 
(1606 cm
1
) compared to salbutamol presented as the commercial sulphate (1617 cm
1
) 
(Supporting Information Figure S4). The N  H bend (~ 1616 cm
1
) of salbutamol was also 
modified with increasing concentrations of sulphate (Figure 5). At 35 mM sulphate, a peak 
height ratio (1606 cm
1
 and 1617 cm
1
) change was detected. The peak height ratio continued to 
change with increasing sulphate concentrations until the 1606 cm
1
 peak disappeared with 158 
mM sulphate. The peak height ratio, determined using the peaks at ~ 1606 cm
1
 and ~1618 cm
1
, 
was used to calculate the percentage of salbutamol bound to sulphate in solution and this was 
plotted against the free sulphate concentration in order to calculate a log affinity constant of 0.85 
± 0.03, assuming a 1:1 association (note: we did not consider a 1:2, salbutamol sulphate ratio to 
be relevant in solution due to the weak binding and the relatively low amount of counterion 
present). In the presence of 1H2NA the spectral splitting of the 1615 peak indicated that an ion
pair was formed. However, these spectral changes occurred at a 10 fold lower concentration 
compared to the sulphate counterion. Unlike for the sulphate counterion the overlapping signals 
made it impossible to calculate the peak ratio and construct a binding curve (Figure 5). Attempts 
were made to use UV/Vis spectroscopy to support the IR data, but the salbutamol base lambda 
max at 276.43 nm did not shift (Supporting Information Figure S5). To facilitate the 
subsequent  and  studies, the HYSS microscpeciation software (Protonic Software, 
UK) was used to calculate the optimum ratio for salbutamol: counterion that would generate 
ionpairs at pH 7.4 employing the measured affinity constant for salbutamol sulphate (given that 
Page 20 of 37
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 20
the 1H2NA binding was ca. 10fold stronger). These results suggested that at a 1:10 drug to 
counterion molar ratio with the ionpaired species would be formed (data not shown). 
 
   
Figure 5. FTIR spectra of (A) salbutamol base in the presence of increasing sulphate and (B) 
salbutamol base in the presence of increasing 1H2NA concentrations in the liquid state (80 % 
deuterated water and 20 % deuterated methanol, pH 6.5). The number denotes the concentration 
(mM) of counterion present against a fixed salbutamol base concentration (42 mM).  
), ("%""$(	(	" 
The flux of the commercial salbutamol sulphate mixture through the tracheal tissue was 
1.17 ± 0.27 µg/cm
2
/min (Figure 6). This flux for salbutamol sulphate was similar to salbutamol 
1H2NA (1.49 ± 0.14 µg/cm
2
/min), but both systems containing the counterions displayed a 
significantly greater flux than that of salbutamol base alone at 0.34 ± 0.07 µg/cm
2
/min (%< 
0.0001, twotailed, unpaired, Student’s test). The cumulative mass of salbutamol base (0.00178 
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M) that transported into the receiver solution was 97.30 ± 18.94 µg/cm
2
 at 360 min (Figure 6). 
The cumulative mass of salbutamol (0.00178 M) that transported across the guinea pig tracheal 
tissue when presented with an excess of the hydrophobic counterion, 1H2NA (0.0178 M) at 360 
min was 335.08 ± 28.16 µg/cm
2
 and this was significantly greater (%< 0.0001, twotailed, 
unpaired, Student’s test) than salbutamol base alone (Figure 6). The lag time to steadystate 
flux of salbutamol in the presence of 1H2NA was significantly higher than that of the base 
(138.91 ± 8.27 min with 1H2NA vs. 87.60 ± 5.54 min for the base; %< 0.0001, twotailed, 
unpaired, Student’s test), whereas the lag time for salbutamol sulphate crossing the lung 
tracheal tissue was lower than the base at 28.97 ± 6.52 min (%< 0.0001, twotailed, unpaired, 
Student’s test). The apparent permeability (Papp (cm/s)) of salbutamol base in the presence of 
1H2NA and in the presence of sulphate was also significantly greater than the base alone (%< 
0.0001, twotailed, unpaired, Student’s test) (Table 1). 
 
Figure 6. Transport of salbutamol base 
(0.00178 M, pH 7.4), salbutamol sulphate 
(0.00178 M : 0.00037 M, pH 7.4) and  
salbutamol in the presence of excess 
1H2NA (0.00178 : 0.0178 M, pH 7.4) 
across guinea pig lung tracheal tissue into 
saline (pH 7.4). Each point represents the 
mean cumulative mass per area ± SD ( = 
512). Twotailed, unpaired, Student’s -
test, (***) %< 0.0001 vs. salbutamol base. 
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Table 1. The flux (µg/cm
2
/min) and apparent permeability (Papp) of salbutamol base, salbutamol 
sulphate, and salbutamol in the presence of excess 1H2NA, through guinea pig tracheal tissue 
into saline pH 7.4 at 37 °C. The concentration of salbutamol remained constant at 0.00178 M. 
Each value of the flux represents the mean ± standard deviation. 
Drug Detection 
(min) 
Slope vs. 
Time (min) 
Flux 
(µg/cm
2
/min) 
R
2
 Papp 
(cm/s) 

Salbutamol base 60 120  360 0.34 ± 0.07 0.9992 1.31 ± 0.28 x 10
5
 5 
Salbutamol 
Sulphate 
(commercial) 
30 60  360 1.17 ± 0.27 0.9717 4.57 ± 1.08 x10
5
 12 
Salbutamol 
1H2NA 
180 180  360 1.49 ± 0.14 0.9964 5.84 ± 0.57 x10
5
 5 

).8/	/2"+" (" (" %/	" (/	%	"		+
'&9:;- 	"+"	$ 	%$/	"(/( "	 
The superfusion of salbutamol base (1 µM) in deionised water (pH 7.4) caused an 84.24 ± 
0.64 % inhibition of the tissues with an OT50 of 5.00 ± 0.00 min and an OT75 of 8.75 ± 1.03 min. 
Both the OT50 and OT75 for salbutamol sulphate was significantly faster compared to salbutamol 
base alone (%< 0.01 and %< 0.05 respectively, one way ANOVA KruskalWallis test with post
hoc Dunn's multiple comparison test) (Table 2). However, the total percentage inhibition of the 
tissue superfused with salbutamol sulphate was similar to the base (%> 0.05, one way ANOVA 
KruskalWallis test with posthoc Dunn's multiple comparison test). The tissue recovery indices 
of the base and sulphate forms of salbutamol were also similar (%> 0.05, one way ANOVA 
KruskalWallis test with posthoc Dunn's multiple comparison test). All of the tissues recovered 
to 100% of the predrug value and the tissues that had been treated with salbutamol were not 
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significantly different (%> 0.05, one way ANOVA KruskalWallis test with posthoc Dunn's 
multiple comparison test) compared to the drug free controls (Table 2). 
Salbutamol (1 µM) in the presence of excess 1H2NA (10 µM) had an OT50 similar to that 
of salbutamol base (%> 0.05, one way ANOVA KruskalWallis test with posthoc Dunn's 
multiple comparison test). However, the OT75 for salbutamol in the presence of 1H2NA was 
significantly faster with an onset time of 4.38 ± 0.89 minutes compared to 8.75 ± 1.03 minutes 
for the base (%< 0.05, one way ANOVA KruskalWallis test with posthoc Dunn's multiple 
comparison test). The inhibition of contraction by salbutamol in the presence of 1H2NA was also 
greater than salbutamol base alone, with a total inhibition of 94.13 % (%< 0.05, one way ANOVA 
KruskalWallis test with posthoc Dunn's multiple comparison test). The time for the tissues to 
reach 50 % recovery compared to the predrug values, for both salbutamol base and salbutamol 
in the presence of 1H2NA, was approximately 50 minutes (%> 0.05, one way ANOVA Kruskal
Wallis test with posthoc Dunn's multiple comparison test). However, the average time taken for 
the tissues to recover to 75% of the predrug value for salbutamol in the presence of 1H2NA was 
faster (%< 0.01, one way ANOVA KruskalWallis test with posthoc Dunn's multiple comparison 
test). All of the tissues recovered to 100 % of the predrug value and were not significantly 
different from both controls (%> 0.05, one way ANOVA KruskalWallis test with posthoc 
Dunn's multiple comparison test) (Table 2).
 
Table 2. The percentage control (%) of tissues after drug addition, and percentage tissue 
recovery at 360 minutes post dosing, onset time (OT50, OT75) to achieve 50% or 75% control 
(predrug) value and recovery time (RT50, RT75) to return to 50% or 75% of control (predrug) 
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value (minutes) for salbutamol base (SAL, 1 µM), salbutamol sulphate (SAL Sulphate, 1 µM) 
and salbutamol in the presence of 1H2NA (1 µM: 10 µM)  at pH 7.4 in isolated guinea pig 
trachea. Results expressed as mean ± SEM. A one way ANOVA KruskalWallis test with post
hoc Dunn's multiple comparison test was used for statistical comparison: (*) %< 0.05 vs. 
salbutamol base; (**)%< 0.01 vs. salbutamol base. 
 
 Test substance 
 Control Water SAL SAL Sulphate SAL + 1H2NA 
OT50 (min)   5.00 ± 0.00 2.51 ± 0.00** 4.37 ± 0.62 
OT75 (min)   8.75 ± 1.03 3.89 ± 0.97* 4.38 ± 0.84* 
Control (%) 108.19 ± 5.90 106.04 ± 4.97 15.79 ± 0.64 17.98 ± 2.33 5.87 ± 1.96** 
RT50 (min)   53.34 ± 2.64 53.34 ± 0.00 51.25 ± 2.08 
RT75 (min)   84.17 ± 2.50 74.17 ± 0.00 61.67 ± 0.00** 
Control (360 
min; % ) 
108.19 ± 3.74 104.88 ± 4.89 101.97 ± 2.13 99.07 ± 2.11 102.64 ± 2.98 
 5 3 5 3 4 
 
4.Discussion 
Of the different drugcounterion combinations assessed   only the salbutamol 
1H2NA complex had an effect on airway smooth muscle relaxation (ASM) when compared with 
salbutamol base. It could be argued that the enhanced smooth muscle relaxation in the presence 
of 1H2NA could have been a consequence of this molecule having an independent action on 
ASM as it was presented to the tissue in a molar excess compared to salbutamol base. There is 
little information in the literature regarding the effect of 1H2NA on biological tissues, but 
Groeben and Emala
19
 did evaluate the effect of xinafoic acid (1H2NA) on ASM, in particular its 
ability to bind to the β2AR. In this previous work it was concluded that 1H2NA had no direct 
airway irritant effects, had no direct bronchodilating effects  and it was thought that it did 
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not interfere with β2AR binding  nor impair the binding of salmeterol to β2AR. The 
data from the present study, which showed an effect of 1H2NA with salbutamol, but not with 
salmeterol, concurred with the previous suggestions that the 1H2NA effects were not dependent 
on any direct interaction with β2receptors. 
The ability of drugion pair formation to enhance drug absorption has been reported in 
the literature.
1,6,20
 In addition, it has already been established in previously published work that a 
number of anionic drugs can form complexes with 1H2NA. However, there seems to be an 
absence of studies that determine the ionpair association using direct spectroscopy and then go 
on to understand their pharmacological effects. This was presumably because the ionic and other 
noncovalent interactions (i.e. hydrogen bonding) that occur between the ionic drug and the 
counterion during ionpair formation are relatively weak,
21,22
 and in aqueous solvents the water 
signals make the detection of any spectra shifts difficult to observe.
23,24
 Despite these issues, in 
the present study, we attempted to generate direct spectroscopy evidence of ionpair formation, 
but as a simple aqueous solution was not capable of dissolving salbutamol and the test counter
ions, methanol was added to aid solubility. It was known that the presence of methanol would 
influence the absolute values for the affinity constant compared to a pure water system, but it 
was believed that by keeping a constant solvent system across the measurements it would not 
detract from the comparative measurements made in the current study. In addition, there are 
methods available to predict affinity constants in water from experimental data with water 
methanol solvents.
25
  
The FTIR spectroscopy data generated in this study substantiated that salbutamol formed 
an ionpair with sulphate and 1H2NA. However, a full binding curve could only be obtained for 
the salbutamol sulphate salt. The spectral shifts for 1H2NA occurred at a 10 fold lower 
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concentration compared to salbutamol, and despite not being able to generate an absolute value 
for the binding affinity between salbutamol1H2NA, the data allowed us to predict with some 
confidence that the salbutamol1H2NA ionpair would be formed at the 1:10 ratio of 
drug:counterion that was used across all the experiments.
26
 
For salbutamol, which is thought to enter the tissue primarily via the paracellular route,
27
 
the formation of the ionpairs could have modified tissue uptake by making the transcellular 
route more favourable since the formation of a complex would have to some extent reduced the 
charge and hydrophilicity of the salbutamol molecule.
1
 The comparative effects of this counter
ion enhanced drug transport process would be much less for formoterol and salmeterol because it 
is thought that these molecules are naturally transported by the transcellular route, even without 
the addition of a counterion, due to their greater hydrophobicity 
28
 It has been hypothesised that 
once deposited into the airways formoterol moves efficiently across the airway epithelium and 
into the lamina propria where it diffuses towards ASM by partitioning into the lipid bilayer and 
then progressively leaches out to interact with the β2AR active site.
29
 Salmeterol, contains a 
longer side chain than the shorter acting β2agonist salbutamol that makes it > 10 000 times more 
lipophilic and so it has also been hypothesised to move readily through the epithelial cell 
membrane.
30
  
Although superfusion studies were not completed in this work for salmeterol or 
formoterol, previous studies have shown that both formoterol and salbutamol display a faster 
onset time compared to salmeterol.
31,32
 Furthermore, formoterol is known to be more potent than 
salmeterol in both   and   studies.
31,32
 This information from the literature 
compliments the lung function studies in the current work where formoterol seemed to have a 
greater degree of inhibition compared to salmeterol alone and in the presence of counterions 
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across the concentration range (0.1 – 10 µg kg
1
).
33
 This suggested that the  systems used 
in this study were working well. The lack of a significant difference observed when the counter
ions were combined with formoterol (figure 3) or salmeterol (figure 4) may be due to the choice 
of counterions. The ability to form an ionpair that will remain complexed for long enough to 
influence its pharmacological behaviour, is related to the chemical structure and physicochemical 
properties of the parent drug and the counterions present. The the curve for salmeterol in the 
presence of the maleate counter ion was significantly different from salmeterol xinafoate, and the 
dose response profiles for salmeterol base and salmeterol aspartate were very different to 
salmetrol xinafoate (figure 4). These small differences could be exploited by investigating 
alternative counterions which may have a strong affinity for the parent drug. 
As the 1H2NA counterion has been previously shown to form ionpars with a wide 
range of drug molecules,
1
 it was thought that it would be worthwhile to further understand the 
transport of salbutamol 1H2NA into lung tissue using an  model. As the influence of ion
pairing on a range of cell lines has previously been established  ,
1,34
 in this work we 
wanted to use exvivo tissue such that we could understand not only passage through the 
epithelial barrier, but also drug permeation across through pulmonary tissue as this has relevance 
to both locally administered and systemically administered agents. Although we accept only a 
limited amount of drug is absorbed through the tracheal tissue, this section of the respiratory tract 
provided significant rigidity to allow drug transport to be assessed. A 60 min equilibration time 
was needed to ensure the Franz cells were secure, free of bubbles and at a temperature of 
37°C.
35,36
 As these conditions remained constant throughout the work it was unlikely that the 
application of the liquid, which can change apical ion channel abundance, and hence cause 
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increased fluxes due to activation of fluid homoeostasis mechanisms had an effect on the data set 
trends.
37
 
For the lung trachea transport studies the hypothesis was that ionpair formation 
enhanced the ability of salbutamol to move into the tissue. Salbutamol base at pH 7.4 is very 
hydrophilic with a cLog D7.4 of 1.32 (MarvinSketch, ChenAxon Ltd) and it is fully ionised 
(calculated amine pKa = 9.02 ± 0.028) from pH 8 and below; therefore there is not a pH 
dependant change in the transport of salbutamol across this range.
38
 Although, lung lining fluid is 
slightly acidic (pH 6.9) 
39
 the transport studies were conducted at pH 7.4 to prevent a pH gradient 
across the cells as this could influence transport. Furthermore, a pH of 7.4 is typically used in 
cell culture models when characterising salbutamol transport.
40
 These physicochemical 
properties enable fast dissolution of the parent drug to occur when it is administered as a solid, 
but salbutamol’s polarity results in only a moderate affinity with the cellular epithelium of 
tracheal tissue. Evidence for the transcellular route being the main path of entry into the 
pulmonary tissue has been generated through transport inhibition studies using other charged 
molecules such as amino acids.
27
 More recent studies have also suggested the involvement of 
organic cation transporters (OCTs) in tissue accumulation and cellular uptake of inhaled 
drugs.
41,42
 As salbutamol base carries a net positive charge at physiological lung pH,
43
 OCTs 
may be involved in the absorption and clearance processes for this drug in the lung without the 
formation of a ionpair,
42,43
 but the OCT’s capacity to take up a neutral ionpair would 
presumably be diminished.  
The association of 1H2NA with salbutamol would generate a larger, more neutral 
molecule which would be inherently more hydrophobic than the parent.
34,44
 It is these changes in 
physicochemical properties which would most likely drive the increase in affinity of the ionpair 
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for the lung tissue compared to the parent drug.
45,46
 The increase in transport lagtime, which 
traditionally occurs as a consequence of an increase in molecular size of a compound,
47
 and the 
higher Papp of salbutamol in the presence of 1H2NA support this hypothesis. The Papp values 
reported in the literature for salbutamol range by 2 orders of magnitude from 1.5 x 10
8
 (porcine 
tissue)
48
 to 5.2 x 10
6 
cm/s (Calu3 cells).
49
 The salbutamol base Papp of 1.31 ± 0.28 x 10
5
 cm/s 
reported in the current work was approximately double the highest of these previously reported 
values and this was considered to be due to the different permeability of guinea pig trachea. No 
previous work has used this tissue to test drug transport and our transport data suggested that the 
barrier was confluent. 
The Sulphate counterion could also have a similar effect to 1H2NA on salbutamol 
transport, but the charging on the sulphate at pH 7.4 would mean that a neutral complex is 
unlikely to be formed and the transport of the salbutamol sulphate may be a little more complex 
than the 1H2N salbutamol ionpair. However, it was noteworthy that the sulphate counterion 
displayed the ability to alter the transport into the tissue, even at the 1:2 drug:counterion ratio. 
The cLog D7.4 of 1H2NA is predicted to be 0.53 (MarvinSketch software (ChemAxon)) making 
it a more lipophilic ionpairing agent compared to the sulphate, cLog D7.4 5.54 (MarvinSketch 
software (ChemAxon). Assuming that salbutamol and 1H2NA are forming an ionpair in 
solution, the overall complex would be more hydrophobic compared to the sulphate counterion 
complex and thus one may expect the former to show greater affinity to tissue and a greater 
propensity to be transported via the transcellular route.
46
 Ionpair transport across the membrane 
will not be hindered by charged proteins in the ECM as may be the case for weak bases such as 
salbutamol
50
 and this could aid the transport rates across the tissue.  
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The  studies that investigated the relaxant activity of salbutamol in the presence of 
the counterions in isolated guinea pig tracheal tissue showed only a marginal effect of the 
salbutamol:1H2NA complex. The small magnitude of the response in the isolated tissue model 
suggested that the pharmacology of the drugs action was not dramatically modified as a 
consequence of ionpair formation. Therefore, it was proposed that the ionpair broke down once 
taken up into the tissue. This was supported by the fact that the weaker of the two ionpairs, the 
salbutamol sulphate complex, did not show any effect. It was interesting however that the 
delayed lag time showed in the transport studies did not have any consequences on the 
pharmacological indices measured both  and . In fact the 1H2NA ionpair had a 
significantly faster onset rate (OT75 only) in addition to a greater degree of inhibition compared 
to the base alone, which would not be predicted when analysing drug transport across lung 
trachea. It was also surprising that the faster onset of pharmacological action was coupled with a 
significantly faster recovery rate, not observed with salbutamol sulphate. It was expected that the 
1H2NA counterion would provide a slower recovery rate due to an increase in the 
hydrophobicity of the complex, but perhaps if the ionpair complex was dissociating in the tissue 
this resulted in a complex relationship between the transport and pharmacological activity. 
 
5.Conclusions 
 The results from this study provide evidence that the counterions included in 
pharmaceutical salts are important in determining the biological behaviour of the parent drug 
molecule when delivered by the inhaled route. These results need confirming using 
pharmaceutical salts in the solid state in man, but if this is achieved it will have significant 
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implications for the choice of counterion for inhaled drugs. These data from our study suggest 
that when counterions are switched in generic products, careful characterisation of the 
pharmaceutical alternative’s properties must be undertaken prior to medicine approval. 
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